BioAmicus Complete probiotic drops for infant tummy and skin issues
Official title: A Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Dietary Supplement BioAmicus Complete (Oral Drops; a Mixture of 10 Strains of Lacto- and Bifidobacteria) in Managing Functional Gastrointestinal Disorders and Cutaneous Symptoms of Food Allergy in Infants During the First Months of Life
Run by NovoNatum Ltd · NCT07444008 · Data updated 2026-11-12
This test will see if daily BioAmicus Complete probiotic drops help infants (about 1 to 4 months old) with colic, constipation, diarrhea, reflux, or atopic dermatitis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 1 Month to 5 Months |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | NovoNatum Ltd Industry-sponsored |
| Locations | 1 site (Saint Petersburg) |
| Status | Recruiting |
| Started | March 16, 2026 |
| Main results expected | June 30, 2026 |
| Study ends | July 30, 2026 |
| Registry record updated | May 11, 2026 |
| Trial ID | NCT07444008 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Full-term or later-preterm infants aged 1 month to 4 months 28 days with colic, constipation, diarrhea, reflux, or cutaneous manifestations of food allergy whose Russian-speaking parents can complete a daily diary are ideal candidates.
✕Probably not a fit
Infants with congenital pathology or other medical conditions that interfere with participation, those using excluded lactase or other probiotic products, and very early preterm infants are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, single-blind, placebo-controlled trial enrolling about 140 infants randomized 1:1 to BioAmicus Complete oral drops or placebo for 25 days, with allowed symptomatic therapies such as simethicone or dill water. Infants aged 1 month to 4 months 28 days who present with functional gastrointestinal symptoms (colic, constipation, diarrhea, reflux) or cutaneous signs of food allergy are eligible; very early preterm infants and those with interfering conditions are excluded. Parents/guardians complete a daily observation diary to record symptoms and treatment adherence, and outcomes compare symptom changes between the probiotic and placebo groups. The sponsor is NovoNatum Ltd and the single listed site is a city polyclinic in Saint Petersburg, Russia.
Why it matters
Potential benefit: If effective, the drops could reduce GI upset and skin allergy symptoms in young infants and lower the need for other symptomatic treatments.
How similar studies have gone: Previous trials of various probiotics for infant colic and atopic dermatitis have shown mixed results, with some positive findings for certain strains but no consistent, widely replicated success for multi-strain products.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The child's parents/guardians speak Russian, have been informed about the study's purpose, understand its essence, are aware of their rights, and have signed the informed consent form. * Diarrhea or constipation accompanied by colic and/or regurgitation (gastroesophageal reflux, GER). * Cutaneous manifestations of food allergy. * The child was born at term or preterm, but not before the 7th month of gestation. * Age at the time of parental informed consent: from 1 month to 4 months and 28 days. * The child is on breastfeeding, formula feeding, or mixed feeding. * The child has no other health conditions that would require a specialized diet. * The parents/guardians are able and willing to regularly complete the proposed observation diary form. Exclusion Criteria: * The child has a congenital pathology or any other conditions/diseases/clinical manifestations that may interfere with participation in the study. * Use of lactase supplements. * Use of other probiotic products, antibiotics, enteral antiseptics, antifungal, or antiprotozoal medications. * The child was born preterm (before the 7th month of gestation).
Where it's running
-
St. Petersburg State Budgetary Healthcare Institution "City Polyclinic No. 43"
Saint Petersburg, Russia Recruiting
Study contacts
- Study coordinator: Oleg Tyrsin
- Email: vb@novonatum.com
- Phone: +7 985 784 3151
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gut health follow-along with Peachbiotic in adults
This single-arm study tests whether Peachbiotic taken daily for 12 weeks helps adults with gut symptoms feel better.
-
Prebiotic and Probiotic Combo for Constipation Symptoms
This study tests whether adding 1-kestose to a probiotic (BBH112) helps adults with constipation-related symptoms see more relief and better quality of life.
-
Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults
A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.
-
Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin
This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.
-
ADBest TREAT Registry for adults with atopic dermatitis
A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.
-
Constipation Prevention Checklist in hip surgery patients
A simple checklist is used to see if hip surgery patients can stay regular by staying hydrated, eating well, moving early, and using abdominal massage.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.